PHARMANOVIA

Pharmanovia in-licenses catumaxomab from Lindis Biotech for malignant ascites treatment. The agreement grants Pharmanovia exclusive marketing rights. Catumaxomab targets EpCAM-positive carcinomas in adults ineligible for systemic anticancer therapy. Pharmanovia aims to reintroduce the drug to the market, pending regulatory approval. Lindis Biotech received a positive opinion from EMA's CHMP in October 2024, with EU marketing authorization expected by year-end.

Lindis Biotech GmbH partners with Pharmanovia to commercialize Catumaxomab, a bifunctional antibody therapy for malignant ascites, pending EMA approval. The drug targets EpCAM-positive carcinomas, aiming to improve patient quality of life and potentially extend lifespan.

Pharmanovia signs agreement with Lindis Biotech to commercialize catumaxomab for malignant ascites, pending EMA approval.